Skip to main content
Premium Trial:

Request an Annual Quote

Dimerix, Takeda in GPCR Screening Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dimerix Bioscience said today that it will help Takeda Cambridge Limited study G-protein coupled receptors (GPCR) that Takeda believes may be developed into drug compounds.

Under the agreement, Australia-based Dimerix will use its GPCR-HIT platform to form complexes called heteromers that can be used to screen for and profile compounds for Takeda Cambridge, which is a UK-based subsidiary of Japan's Takeda Pharmaceutical.

"Dimerix' GPCR-HIT platform enables the development of more specific drugs that take into account the signaling profile of GPCRs acting in heteromeric complexes," Dimerix CEO Tim Grogan said in a statement.

The GPCR-HIT technology, which Dimerix acquired from its developers at the University of Western Australia, can expand the scope of GPCR drug discovery efforts by identifying compounds with signaling that is mediated through GPCR heteromers.

Financial terms of the agreement were not released.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.